ArticleEmerging infectious diseases2024
Respiratory Syncytial Virus Prevalence and Risk Factors among Healthy Term Infants, United States.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Epidemiological characteristics and seasonal dynamics of six respiratory pathogens in children: a 2-year retrospective cross-sectional study in Chengdu, China.BMC pediatrics · 2026Article
- Multiple co-infections and risk of severe outcomes in children with respiratory syncytial virus infection.BMC infectious diseases · 2026Article
- Temporal trends in respiratory syncytial virus-related infant mortality and hospitalizations in the United States.Pediatric research · 2026Article
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Article
- Shifting patterns of pediatric respiratory viruses during the SARS-CoV-2 pandemic: a retrospective observational study.BMC infectious diseases · 2026Observational
- Viral Respiratory Infections in Djibouti: Insights from Two Years of Pilot Surveillance.Viruses · 2025Article
- Direct Out-of-Pocket Costs of NirsevimabInfection & chemotherapy · 2025Article
- Early risk identification for recurrent wheezing in children with respiratory syncytial virus infections.American journal of translational research · 2025Article
- Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database.Kansas journal of medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In a population-based birth cohort study of respiratory syncytial virus surveillance in the United States, 897/1,680 (53.4%) children were infected during infancy; 25 (2.8%) of those were hospitalized. Among symptomatic infants, 143/324 (44.1%) had lower respiratory tract infections. These data provide benchmarks to monitor effects of maternal vaccines and extended half-life monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.